Navigation Links
Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
Date:7/9/2008

eviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic range of APD791 and the exposures which may produce minimal, moderate or near-complete inhibition of serotonin-mediated amplification of platelet aggregation; the potential for APD791 to provide advantages over currently available therapies; determination of the best approach to advance APD791 into Phase 2 clinical trials; the tolerability, side effects and efficacy of APD791; the role of serotonin in thrombosis and in increasing cardiovascular risk; how APD791 is believed to work and its intended use and therapeutic potential; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings w
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
3. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
6. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
7. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
8. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
9. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
10. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
11. Isis Pharmaceuticals Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... BOULDER, Colo. , Sept. 2, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Securities Healthcare Conference in Boston.  The public is ... webcast on the Array BioPharma website.Event: Wells Fargo ... , Thursday, September 10, 2015Time:  , 10:20 a.m. ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 About ... is a malignant condition characterized by increased production of ... affects B-lymphocytes and then it can spread to other ... at later stages because of the slow buildup of ... the malignancy spreads to the spleen, liver, and lymph ...
(Date:9/2/2015)... , Sept. 2, 2015 STAAR Surgical Company ... of implantable lenses and delivery systems for the eye, today ... P. Wall to the Company,s Board. ... a Boston -based investment firm, for more ... the Board of Directors, and chair of the Corporate Governance ...
Breaking Medicine Technology:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3William P. Wall Appointed to STAAR Surgical Board of Directors 2
... says: Wrong Question Asked. Wrong Children Studied. Wrong,Conclusions ... Centers for Disease,Control and Prevention (CDC) study released ... vaccine and autism. The National Autism Association (NAA),says ... public concern over a,vaccine-autism connection and raises several ...
... BRUSSELS, Belgium and GENEVA, Sept. 3 Artelis ... in CHO based monoclonal antibody,production with the achievement ... This record level was accomplished by applying two ... cell line rapidly generated by industry leading scientists ...
Cached Medicine Technology:CDC Misses Target With Flawed MMR/Autism Study 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3
(Date:9/3/2015)... ... September 03, 2015 , ... ... Bob Anders and Kelley Chapman will be joining the company’s executive leadership team ... Anders has over 30 years’ experience in healthcare product and project management. He ...
(Date:9/3/2015)... ... 03, 2015 , ... The partnership will leverage Fidson’s strong ... services to promote LodonalTM in Nigeria. The distribution will become effective, upon completion ... of the product. , Managing Director, Fidson Healthcare Plc, Dr Fidelis Ayebae, expressed ...
(Date:9/2/2015)... ... , ... The Aspen Clinic (TAC), located in Basalt, Colorado, today ... inspiring wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, Executive Director ... to fitness - we are much more than a gym. Our fitness and ...
(Date:9/2/2015)... ... ... One can hardly argue against the fact that more and more people ... These devices are being used as GPS, to make purchases, and yes, even to ... positive singles can now join the prestigious social ranks of e-dating. , Recently, ...
(Date:9/2/2015)... Washington, DC (PRWEB) , ... September 03, 2015 ... ... stacks of nominations to determine who among America’s policymakers, public servants, activists, corporate ... on the nation’s health care. This year, that process led the magazine to ...
Breaking Medicine News(10 mins):Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3
... June 8, 2010The new Center for Medicare and Medicaid ... and implementing payment initiatives, continuously monitor their impact, and ... in order to realize the potential for improved health ... Health Affairs article by Commonwealth Fund researchers. ...
... A quick, painless eye measurement shows promise as ... early stages, and to track the effectiveness of treatments, ... a multicenter study. "This technique has the potential ... measure structural changes in the central nervous system, both ...
... think they have discriminating tastes when it comes to romantic ... women are greatly influenced not only by what their friends ... by the opinions of complete strangers. "Humans don,t exist ... that we have evolved mechanisms that let us take advantage ...
... with non-melanoma skin cancer may be at increased risk ... to research led by St. Jude Children,s Research Hospital ... Childhood Cancer Survivor Study (CCSS) who were diagnosed with ... aggressive cancer within 15 years, said Gregory Armstrong, M.D., ...
... Now for the U.S. Army Medical Research and Materiel ... (ATACCC) conference Aug. 16-19, St. Pete Beach, Florida. ... meeting to focus on the battlefield medical needs of ... surgery and medicine. The conference generates intense discussion, focused ...
... Montreal, 7 June 2010 The Institute for Research ... Montral launches B2Discovery, a new research funding model that ... community to help accelerate the discovery of new anti-cancer ... of several Canadian athletes at the Vancouver Winter Olympics, ...
Cached Medicine News:Health News:Center for Medicare and Medicaid Innovation must implement payment reforms rapidly 2Health News:Center for Medicare and Medicaid Innovation must implement payment reforms rapidly 3Health News:Simple eye test measures damage from multiple sclerosis, UT Southwestern researchers find 2Health News:Strangers influence our dating preferences 2Health News:Strangers influence our dating preferences 3Health News:Non-melanoma skin cancer may help identify survivors at increased risk for future cancers 2Health News:B2Discovery: Entrepreneurs and researchers join forces to conquer cancer 2
Inquire...
Inquire...
Inquire...
These claw forceps are single-action with sturdy teeth that provide a broad grasping area to hold the gallbladder securely during removal....
Medicine Products: